Cagrilintide in Australia

Long-acting amylin analogue. Cagrilintide is a lipidated version of amylin, the hormone the pancreas releases with insulin to signal fullness to the brainstem. Novo Nordisk built it as a once-weekly compound and is testing it both by itself and in a fixed pairing with semaglutide (CagriSema). For researchers it opens up a way to look at the amylin pathway apart from the incretin pathway.

Satiety signalling: pharmacology of the amylin receptor acting in the area postrema. Weight regulation: endpoints from the dose-ranging Phase 2 trial. Combination research: the added effect seen with GLP-1 agonists in REDEFINE. Gastric emptying: scintigraphy endpoints used in mechanistic studies. A Phase 2 dose-ranging trial (Lau et al., Lancet 2021) reported average weight reductions reaching 10.8% at 26 weeks with cagrilintide on its own. In Phase 3, the REDEFINE trials of the CagriSema combination reported larger reductions than semaglutide alone. Preclinical work looks at how lean mass is preserved and how the compound interacts with GLP-1 signalling.

The Phase 2 dose-ranging trial reported average weight loss of 6.0% to 10.8% at 26 weeks across its doses against 3.0% for placebo, and in REDEFINE-1 the CagriSema combination reported greater reductions than semaglutide alone.

Gastrointestinal events, chiefly nausea and vomiting, were the events seen most often in the Phase 2 trial, with injection-site reactions reported as well; most were mild to moderate.

In the published Cagrilintide research, the amounts used were 0.3, 0.6, 1.2, 2.4 or 4.5 mg subcutaneous, Once weekly in human, phase 2 rct, cagrilintide alone (Lau DCW et al. (2021)); Escalated to 4.5 mg subcutaneous, Once weekly in human, thorough qt study, cagrilintide alone (Gabe MBN et al. (2024)); 0.6 mg (renal study) or 0.9 mg (hepatic study), Single dose in human, phase 1, cagrilintide alone, renal and hepatic (n=32) impairment (Nielsen MJF et al. (2026)). These are the figures each study reports for its own model, listed in full in the dosage table on this page with links to PubMed. Peptide Aus supplies Cagrilintide for in-vitro research and does not give dosing guidance for people.

A different pathway: amylin-receptor agonism as against triple incretin and glucagon agonism. The two are frequently studied together so that satiety signalling can be separated from incretin effects.

Tirzepatide is a dual incretin agonist while cagrilintide is an amylin analogue, so the pair is examined as complementary mechanisms rather than rival ones.

Each pathway curbs food intake through a separate receptor, and the combination trials reported more weight reduction than either compound managed alone. Study designs often line up cagrilintide, a GLP-1 agonist and the two together so the individual contributions can be teased apart.

The 5mg vial is the starting format for assay development, while the 10mg vial cuts the per-milligram price in half for longer protocols.

With bacteriostatic water added slowly down the inside wall of the vial, then swirled gently. Each vial size lists its suggested volume, and the calculator converts volume to concentration.

Lyophilised: −20 °C, sealed, away from light and moisture. Reconstituted: 2–8 °C, used within 8–12 weeks, never frozen.

The Therapeutic Goods Administration (TGA) has not registered cagrilintide as a medicine in Australia, and it holds no approval for human or veterinary use. Peptide Aus provides it as a research reagent for in-vitro laboratory work only. The Poisons Standard and the Therapeutic Goods Act govern the supply of any substance for human use in Australia, and using the material lawfully is down to the buyer. Anyone seeking a treatment should consult a doctor.

Directly from Peptide Aus, from Australian stock, in 2 vial sizes from $129.99 (5mg) to $229.99 (10mg). Prices are AUD and GST inclusive. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.

It depends on the vial size: 5mg takes 1 mL, 10mg takes 2 mL. That gives 5 mg/mL, 5 mg/mL respectively. The reconstitution steps on this page and the calculator cover the rest.